Rafivirumab

• CAT Number: I041543
• CAS Number: 944548-37-2
• Purity: ≥95%

Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails[1][2][3].
Rafivirumab shows neutralization effect against series of RABV isolates[2].
Rafivirumab binds to antigenic site I of the RABV glycoprotein[3].
Rafivirumab fully neutralizs the wild type ERA439 and N336D R346K with EC50 ranging between 3 and 5 pg/mL[3].
Rafivirumab (3-12 μg/kg,i.m.) together with CR4098 increases survival in syrian hamsters infected with bat rabies viruses[2].

Reference

[1]. Kramer RA, et al. The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur J Immunol. 2005 Jul;35(7):2131-45.
 [Content Brief]

[2]. Franka R, et al. In Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants. Trop Med Infect Dis. 2017 Sep 20;2(3):48.
 [Content Brief]

[3]. Ejemel M, et al. A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis. Sci Rep. 2022 Jun 7;12(1):9403.
 [Content Brief]